RenovoRx, Inc.

NASDAQ:RNXT

Biotechnology

Healthcare
$1.12 -0.86%

-$0.01 today

Market cap
$54.04M
Beta
0.99
P/E (TTM)
-3.4
EPS (TTM)
-$0.32
52W Low $0.70High $1.45

Volume 0.84M

Average 0.29M

RNXT Pre-Tax Margin

Income before tax as a percentage of revenue.

RenovoRx, Inc.NASDAQ: RNXT

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to -625.4%

Pre-tax margin was -625.4% in Q1 FY2026, up 603.0 pp from a year earlier. On a trailing-twelve-month basis it was -824.0%, up 3408.5 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-625.4%+610.7 pp QoQ
Last fiscal yearDec 2025
-994.5%+19503.2 pp YoY
LTMMar 2026
-824.0%+3408.5 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+603.0 pp——
1 year+19503.2 pp——
3 years———
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-994.5%
Year-over-year change
+19503.2pp

Pre-Tax Margin vs competitors

How RNXT compares with its peers on the latest reported figures

  • RNXT's LTM Mar 2026 pre-tax margin of -824.0% is the lowest of the 2 companies compared; the peer median is -345.4%.
  • Its year-over-year change of +3408.5 pp is the highest of 2, against a peer median of -238.7 pp.
RNXT Competitors Peer median
Pre-Tax Margin for RNXT and competitors
Company Period LTM level YoY 3-year change
CELUCelularity Inc.LTM Dec 2025-345.4% -238.7 pp-424.5 pp
RNXTRenovoRx, Inc.LTM Mar 2026-824.0% +3408.5 pp—
PYPDPolyPid Ltd.FY2025— ——
MAIAMAIA Biotechnology, Inc.FY2025— ——
ANVSAnnovis Bio, Inc.FY2025— ——
LTRNLantern Pharma Inc.FY2025— ——
Peer median (excluding RNXT) -345.4%-238.7 pp-424.5 pp

Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00043K1.12M
Cost of Revenue0000327K
Gross Profit00043K796K
Gross Margin———100.0%70.9%
Research & Development3.04M4.3M5.67M6.03M6.27M
Selling, General & Admin2.63M5.65M5.73M4.99M7.04M
Operating Expenses5.67M9.95M11.4M11.01M13.31M
Depreciation & Amortization9K6K6K02K
EBITDA(5.48M)(9.83M)(10.12M)(8.81M)(11.17M)
EBITDA Margin———-20497.7%-994.3%
Operating Income(5.67M)(9.95M)(11.4M)(10.97M)(12.51M)
Operating Margin———-25511.6%-1114.0%
Interest Income70K57K0384K427K
Interest Expense904K57K108K00
Other Income / Expenses(653K)61K1.16M2.16M1.34M
Income Before Tax(6.32M)(9.89M)(10.23M)(8.81M)(11.17M)
Pre-Tax Margin———-20497.7%-994.5%
Income Tax Expense00000
Net Income(6.32M)(9.89M)(10.23M)(8.81M)(11.17M)
Net Margin———-20497.7%-994.5%
EPS (Basic)(0.40)(0.54)(0.50)(0.37)(0.32)
EPS (Diluted)(0.40)(0.54)(0.50)(0.37)(0.32)
Weighted Avg Shares17.87M18.1M20.58M23.61M35.33M
Weighted Avg Shares (Diluted)17.87M18.1M20.58M23.61M35.33M

RenovoRx, Inc.

NASDAQ:RNXT

Intrinsic Alpha fair value

Locked

Current Price

$1.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.